Cannabis Law and Access in France

France cannabis law: a prohibited narcotic, with some important carve-outs

Forty-three countries have some form of regulated cannabis access as of 2024. France is not one of them. That surprises people, given how progressive the country appears in other areas of health policy. But if you actually read the French Public Health Code (Code de la santé publique), the picture is pretty clear: cannabis, meaning the plant and any preparation derived from it that contains more than trace levels of tetrahydrocannabinol (THC), is classified as a stupéfiant, a narcotic, under French law. Possession, use, cultivation, and supply are criminal offences.

That baseline has not changed. What has changed, gradually and with considerable friction, is the set of narrow exceptions carved out around it.

For Australian readers: none of what follows is Australian law. France operates under an entirely different regulatory architecture; no TGA, no Poisons Standard, no Special Access Scheme. The comparison is interesting precisely because both countries arrived at "medical cannabis exists, but it's complicated" from very different directions.

A word on terminology helps here. "Stupéfiant" is the legal category that matters in French drug law, and it is a classification of substances rather than a judgement about any single product. Once a substance sits in that category, the default is prohibition, and anything permitted has to be written in as a specific exception. That is the reverse of how many people assume the system works, and it explains why every change in France arrives as a narrow carve-out rather than a broad liberalisation.

The general prohibition and how it's enforced

Under Article L3421-1 of the Code de la santé publique, the personal use of narcotics, cannabis included, carries a maximum penalty of one year's imprisonment and a €3,750 fine. In practice, enforcement has been variable for decades. Police discretion, selective prosecution, and a long public debate about the utility of criminalising users have meant that actual sentences for simple possession are rare. A fixed-penalty fine of €200 was introduced experimentally from 2020, partly as a practical enforcement reform rather than any kind of decriminalisation signal. The offence itself remains on the books.

Cultivation, trafficking, and supply carry substantially heavier penalties, up to ten years and €7.5 million for aggravated trafficking. None of that is unusual by European standards; France signed the 1961 UN Single Convention on Narcotic Drugs and its scheduling framework reflects that.

The gap between the written maximum and the lived reality is a common source of confusion. A statute describes the ceiling, not the typical outcome. Reading only the penalty figures would suggest a harsh regime for users, while reading only the enforcement commentary would suggest a lax one. Neither picture is complete, and anyone comparing countries should keep both the law and its application in view. The same caution applies when comparing France with neighbours such as the Netherlands or Denmark, where formal rules and practice also diverge.

Industrial hemp and the CBD grey zone

Here is where things get genuinely complicated. France has one of the oldest and largest industrial hemp industries in Europe. The country permits the cultivation of Cannabis sativa L. varieties that contain no more than 0.3% THC, reduced from 0.2% following a 2023 regulatory alignment with broader EU agricultural standards. These crops are grown primarily for fibre and seed; they've been part of French agriculture for centuries.

The legal status of cannabidiol (CBD) extracted from those low-THC hemp plants has been genuinely contested. In November 2020, the Court of Justice of the European Union (in the Kanavape judgment) ruled that France could not prohibit the sale of CBD lawfully produced in another EU member state, on the grounds that CBD is not a narcotic. France subsequently adjusted its position. From January 2022, shops, you will find them clustered around areas like Rue Saint-Denis in Paris and scattered across Lyon and Bordeaux, can legally sell CBD flower, resin, and extracts, provided the final product contains less than 0.3% THC.

This is a meaningful shift. It is not, however, full legalisation of anything. The French Medicines Agency (ANSM) retains oversight of any CBD product making health-related claims, and CBD extracts intended for oral consumption sit in a regulatory grey zone that is still being formalised. The distinction between a hemp-derived CBD oil sold as a food supplement and a medicinal product is enforced in theory, though in practice the market has outrun the regulation. I'll admit that's a situation Australian regulators would find familiar.

Two points of vocabulary are worth keeping straight. A THC threshold on a plant variety is an agricultural rule about what may be grown, while a THC limit on a finished product is a consumer-goods rule about what may be sold. They are related but not the same instrument, and mixing them up is a frequent mistake in commentary on European hemp and CBD policy. Likewise, whether a product is classed as a food, a supplement or a medicine depends largely on the claims made about it, which is why regulators pay such close attention to labelling and marketing.

France's medical cannabis pilot programme

France launched a medical cannabis experiment (Expérimentation du cannabis médical) in March 2021, coordinated by the ANSM. The pilot ran for two years and involved roughly 3,000 patients, expanded to approximately 10,000 by early 2023. It was structured as a genuine clinical data-gathering exercise, not a commercial access scheme.

Products used in the pilot were standardised preparations: flower for vaporisation, oral oil, and capsules. They were not dispensed through ordinary pharmacies initially; a separate, controlled dispensing chain was established. Participating patients had conditions within specific defined categories, and prescribing was limited to hospital specialists. The ANSM published interim data throughout the pilot period, and those reports are publicly accessible.

The pilot formally concluded in March 2023. France then extended access on a transitional basis while the government considered a longer-term framework. As of the time of writing, a permanent regulated medical access system has been legislatively proposed but not yet fully enacted; the political path has been slower than advocates hoped. What exists is a transitional continuation of access for patients already enrolled, with formal permanence still pending parliamentary process.

This is not the same as the Australian model, where the TGA's Authorised Prescriber pathway and the Special Access Scheme have been operational since 2016 and 2017 respectively, and where tens of thousands of approvals have now been issued. The French system is, honestly, several years behind where Australia currently sits in terms of practical patient access; though France did move faster on the CBD question.

Why does a "pilot" matter as a regulatory form? Because it lets a government gather structured information under defined conditions before committing to permanent rules. Restricting who may prescribe, fixing which products are used and building a dedicated supply chain are all ways of keeping the experiment controlled and its data interpretable. It is a very different thing from an open access scheme, and the two should not be conflated.

What products were included and what the chemistry looks like

The pilot products were mostly full-spectrum preparations, meaning they contained the broader range of cannabinoids and plant compounds rather than pure isolate. Some preparations were THC-dominant, others CBD-dominant, and ratios varied by indication category. There was no single standardised formulation across all patients.

How those compounds interact with the body's endocannabinoid system, including receptors like CB1 and CB2, is the same biology regardless of which country's regulatory system you're in. The legal landscape changes; the pharmacology does not. The ANSM's interim reports focused heavily on safety monitoring and product consistency rather than efficacy endpoints, which is appropriate for a pilot of that design.

That emphasis is worth understanding. Safety monitoring asks what adverse events are reported and how consistently they are recorded. Product consistency asks whether a given preparation contains what its label says from batch to batch. Efficacy endpoints ask a different, harder question that usually needs a controlled design. A pilot built mainly to observe safety and consistency simply cannot answer the efficacy question, and readers should be wary of anyone who presents it as though it does.

Having read the ANSM's published approach, my view is that the safety reporting structure in particular was well designed, and more rigorous than you might expect from a first-generation pilot. Dense material, but worth the effort.

Recreational cannabis: the current position

France has not legalised recreational cannabis and has no legislation before parliament to do so as of 2024. There have been repeated parliamentary reports recommending various models, a 2021 Senate report, a 2023 National Assembly committee report; and public opinion polling has shifted noticeably toward some form of regulated access. But the political will to pass legislation has not crystallised.

The country watches developments in Germany (which legalised adult personal use and social clubs in 2024 under the Cannabisgesetz) with some interest. French officials have been careful to say they are observing rather than following. My read is that France will move on this eventually, but the timeline is genuinely unclear.

It helps to separate three things that often get blurred: a parliamentary report, which makes recommendations; a bill, which proposes law; and an enacted statute, which changes it. France has produced the first, but not the later two for recreational use. Polling and committee work show the direction of debate, yet they do not alter what is legal on any given day.

What Australian readers should take from this

If you're reading this from Australia, the French framework is a useful comparison point, not a guide to anything actionable. Australian law is governed by the Therapeutic Goods Act 1989, the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons), and state and territory drug legislation. Cannabis products for medical use in Australia require either an Authorised Prescriber approval or a Special Access Scheme Category B application; they are listed in Schedule 8 (controlled drug) of the Poisons Standard for most formulations, or Schedule 4 (prescription only) for low-THC products meeting specific criteria. None of the French pilot framework applies here.

What the French experience does illustrate is that even countries with strong prohibition traditions can run structured, data-focused access pilots. The ANSM approach, limited prescriber categories, standardised products, systematic safety reporting, offers one model of how to gather real-world evidence without creating an unregulated market overnight. Whether that model is superior to Australia's is a separate debate, and one worth having.

For a broader look at how the Australian pathway works, see our explainer on understanding the Special Access Scheme in Australia. For other national frameworks to set beside France, the pages on Czechia and Romania show how other European states have approached the same questions. The TGA's own website remains the authoritative source on Australian rules.

Sources

• Cannabis médical, Agence nationale de sécurité du médicament et des produits de santé (ANSM)
• France Country Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Judgment of the Court (Grand Chamber); Case C-663/18, Kanavape, Court of Justice of the European Union
• Accessing unapproved therapeutic goods, overview; Therapeutic Goods Administration (TGA)

Marcus Hale, Regulatory researcher, TGA & access law